QS Investors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

QS Investors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-39,550	Closed	-$389K	–	1271
2020 Q3	$389K	Sell	39,550 -156,447	-80%	-$1.54M	0.01%	818
2020 Q2	$1.95M	Hold	195,997	–	–	0.03%	502
2020 Q1	$1.73M	Hold	195,997	–	–	0.03%	474
2019 Q4	$1.8M	Sell	195,997 -2,444	-1%	-$17.3K	0.02%	620
2019 Q3	$1.17M	Hold	198,441	–	–	0.01%	733
2019 Q2	$2.38M	Buy	198,441 +115,319	+139%	+$1.24M	0.03%	518
2019 Q1	$1M	Hold	83,122	–	–	0.01%	810
2018 Q4	$1.04M	Sell	83,122 -425	-0.5%	-$5.87K	0.01%	749
2018 Q3	$1.24M	Buy	83,547 +300	+0.4%	+$4.72K	0.01%	764
2018 Q2	$1.4M	Buy	83,247 +444	+0.5%	+$8.62K	0.01%	699
2018 Q1	$1.9M	Sell	82,803 -5,902	-7%	-$131K	0.02%	601
2017 Q4	$2.29M	Sell	88,705 -2,557	-3%	-$51.5K	0.02%	564
2017 Q3	$1.35M	Sell	91,262 -1,525	-2%	-$22.1K	0.01%	732
2017 Q2	$1.29M	Buy	+92,787	New	+$1.37M	0.01%	705

Other funds holding CNCE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QS Investors's CNCE Position: Q4 2020 in Review

QS Investors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2020, closing a stake of 39,550 shares — an estimated $389K sold.

QS Investors first reported a position in CNCE in Q2 2017 and held it in 14 quarters. The position peaked at $2.38M in Q2 2019. 100 funds tracked by Wall St. Rank hold CNCE as of Q4 2020.

QS Investors reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
QS Investors sold 39,550 Concert Pharmaceuticals, Inc. shares in Q4 2020, an estimated $389K.
QS Investors first reported a position in Concert Pharmaceuticals, Inc. in Q2 2017 and held it in 14 quarters.
QS Investors's Concert Pharmaceuticals, Inc. position peaked at $2.38M in Q2 2019.
100 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.